PARC ELISABETH PHARMA
ActiveFrom the official registers: KBO 11 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
The computed 12-month bankruptcy probability of PARC ELISABETH PHARMA is 1.5% (moderate). The 2025 annual accounts show negative equity (-€63,400) and a net result of -€12,285. Equity has been shrinking by about 13% per year since 2018. Its solvency ranks better than 23% of 75 sector peers (NACE 21, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
KBO- Status
- Active since 27-01-2015 Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21201
- Establishment unit
- 2.241.121.454 1083 Ganshoren, since 27-01-2015
- Financial year end
- 31 December
- Peppol
- Reachable since 29-09-2026
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.5%
- Turnover
- €491,912
- Loss
- €12,285
- ▲ 306%
- Equity
- -€63,400
- ▼ 24.0%
- Total assets
- €296,304
- ▼ 22.0%
- Staff
- ≈ 0 FTE
- estimated
Score breakdownraises riskCapped at 59: negative equityNegative equity -€63,400Liquidity: current ratio 0.32, cash €78, halvedlowers riskSize: turnover €491,912, total assets €296,304Founded in 2015Show the evidence
Checked score
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 21% of them on solvency, 12% on liquidity, 51% on profitability and 28% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 46 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2025 -€63,400 View
- Risk: 8 loss-making years in a rowloss in financial year 2025 -€12,285 View
- Caution: Less equity than 83% of companies in pharmaceuticalssector median €51,733 · 75 companies -€63,400 View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
Comparable companies
These companies have the same main activity as PARC ELISABETH PHARMA: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €183,000 and €1.2m, founded between 2008 and 2020.
| Company | Total assets | Gross margin |
|---|---|---|
| PARC ELISABETH PHARMA Ganshoren | €0.3m | €0.04m |
| WANDJI PHARMA INTERNATIONAL Tournai | €0.4m | €0.03m |
| LBS Gent | €0.3m | €0.1m |
| Alchemich Farma Houthalen-Helchteren | €0.3m | €0.05m |
| BIOGEM Vielsalm | €0.2m | €0.09m |
| Dierenartsen Hond en Kat Deinze | €0.3m | €0.08m |
| Pharmentum Kontich | €1.2m | €0.04m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 04-03-2026
- Annual accounts 2024filed on 17-07-2025
- Annual accounts 2023filed on 28-06-2024
- Annual accounts 2022filed on 30-06-2023
Acts in the Belgian Official Gazette
- Amendment of the articles · Legal-form change · Resignations & appointmentsact of 12-12-2023
- Resignations & appointmentsact of 24-08-2023
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about PARC ELISABETH PHARMA
- What is the company number of PARC ELISABETH PHARMA?
- The company number of PARC ELISABETH PHARMA is 0578.934.701. The VAT number is the same number with BE in front: BE 0578.934.701.
- Where is PARC ELISABETH PHARMA based?
- The registered office is at Frans Gasthuislaan 2, 1083 Ganshoren.Company details
- What does PARC ELISABETH PHARMA do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of PARC ELISABETH PHARMA?
- The legal form of PARC ELISABETH PHARMA is Private limited company (BV).
- When was PARC ELISABETH PHARMA founded?
- PARC ELISABETH PHARMA was founded on 27-01-2015.
- Is PARC ELISABETH PHARMA still active?
- Yes, PARC ELISABETH PHARMA is an active enterprise in the KBO register.
- What is the turnover of PARC ELISABETH PHARMA?
- The turnover of PARC ELISABETH PHARMA was €491,912 in financial year 2025, according to the filed annual accounts.Financials
- Is PARC ELISABETH PHARMA profitable?
- In financial year 2025, PARC ELISABETH PHARMA made a loss of €12,285.
- Where can I find the annual accounts of PARC ELISABETH PHARMA?
- PARC ELISABETH PHARMA filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
- When are the next annual accounts of PARC ELISABETH PHARMA due?
- PARC ELISABETH PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.